Literature DB >> 19556932

Twenty-year trends in the incidence and prevalence of diagnosed anogenital warts in Canada.

Erich V Kliewer1, Alain A Demers, Lawrence Elliott, Robert Lotocki, James R G Butler, Marc Brisson.   

Abstract

BACKGROUND: A vaccine has recently been licensed in many countries that protects against the human papillomavirus types 6, 11, 16, and 18. Types 6 and 11 account for approximately 90% of anogenital warts (AGWs). We describe the 20-year trends in the incidence and prevalence of AGWs in Manitoba, Canada.
METHODS: We used linked population-based hospital and physician databases for Manitoba for 1984 to 2004. Cases were identified using tariff (billing) and ICD codes. A case was considered to be incident if it was preceded by a 12-month interval free period of AGWs care. Otherwise, it was deemed to be prevalent. An episode was considered over once a 12-month interval had elapsed without an AGW claim.
RESULTS: Approximately 25,000 Manitobans were diagnosed with AGWs between 1985 and 2004. The annual age-standardized incidence rates peaked in 1992 (men, 149.9/100,000; women 170.8/100,000). In recent years, the rates have been increasing again, particularly for men. The male:female incidence rate ratio increased from 0.76 in 1985 to 1.25 in 2004. The highest incidence rate tended to be in those aged 20 to 24 years. Trends in prevalence were similar. Prevalence in 2004 was 165.2/100,000 for men and 128.4/100,000 for women.
CONCLUSIONS: These population-based findings suggest that AGWs are a substantial burden to Manitobans and that their pattern has changed over time, with incidence and prevalence becoming higher in men than women. Monitoring the future trends in AGWs will provide an early marker of the effectiveness and duration of protection of human papillomavirus vaccination at a population level.

Entities:  

Mesh:

Year:  2009        PMID: 19556932     DOI: 10.1097/OLQ.0b013e318198de8c

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  14 in total

1.  Update on Human Papillomavirus (HPV) Vaccines: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) .

Authors:  Dr M Dawar; Ms T Harris; Dr S McNeil
Journal:  Can Commun Dis Rep       Date:  2012-01-02

2.  Human papillomavirus vaccination for boys.

Authors:  Stephany Quinn; Ran D Goldman
Journal:  Can Fam Physician       Date:  2015-01       Impact factor: 3.275

Review 3.  Quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine: for the prevention of genital warts in males.

Authors:  Karly P Garnock-Jones; Anna R Giuliano
Journal:  Drugs       Date:  2011-03-26       Impact factor: 9.546

4.  The epidemic of human papillomavirus and oropharyngeal cancer in a Canadian population.

Authors:  A C Nichols; D A Palma; S S Dhaliwal; S Tan; J Theuer; W Chow; C Rajakumar; S Um; N Mundi; S Berk; R Zhou; J Basmaji; G Rizzo; J H Franklin; K Fung; K Kwan; B Wehrli; M I Salvadori; E Winquist; S Ernst; S Kuruvilla; N Read; V Venkatesan; B Todorovic; J A Hammond; J Koropatnick; J S Mymryk; J Yoo; J W Barrett
Journal:  Curr Oncol       Date:  2013-08       Impact factor: 3.677

5.  Quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine for the prevention of genital warts in males: profile report. demail@springer.com.

Authors:  Karly P Garnock-Jones; Anna R Giuliano
Journal:  Drugs R D       Date:  2012-12-01

6.  Incidence of anogenital warts in Germany: a population-based cohort study.

Authors:  Angela A Kraut; Tania Schink; Renate Schulze-Rath; Rafael T Mikolajczyk; Edeltraut Garbe
Journal:  BMC Infect Dis       Date:  2010-12-23       Impact factor: 3.090

7.  Prevalence, incidence and risk factors for anogenital warts in Sub Saharan Africa: a systematic review and meta analysis.

Authors:  Cecily Banura; Florence M Mirembe; Jackson Orem; Anthony K Mbonye; Simon Kasasa; Edward K Mbidde
Journal:  Infect Agent Cancer       Date:  2013-07-10       Impact factor: 2.965

8.  The impact of infection on population health: results of the Ontario burden of infectious diseases study.

Authors:  Jeffrey C Kwong; Sujitha Ratnasingham; Michael A Campitelli; Nick Daneman; Shelley L Deeks; Douglas G Manuel; Vanessa G Allen; Ahmed M Bayoumi; Aamir Fazil; David N Fisman; Andrea S Gershon; Effie Gournis; E Jenny Heathcote; Frances B Jamieson; Prabhat Jha; Kamran M Khan; Shannon E Majowicz; Tony Mazzulli; Allison J McGeer; Matthew P Muller; Abhishek Raut; Elizabeth Rea; Robert S Remis; Rita Shahin; Alissa J Wright; Brandon Zagorski; Natasha S Crowcroft
Journal:  PLoS One       Date:  2012-09-04       Impact factor: 3.240

9.  Does HPV type affect outcome in oropharyngeal cancer?

Authors:  Anthony C Nichols; Sandeep S Dhaliwal; David A Palma; John Basmaji; Corina Chapeskie; Samuel Dowthwaite; Jason H Franklin; Kevin Fung; Keith Kwan; Brett Wehrli; Chris Howlett; Iram Siddiqui; Marina I Salvadori; Eric Winquist; Scott Ernst; Sara Kuruvilla; Nancy Read; Varagur Venkatesan; Biljana Todorovic; J Alex Hammond; James Koropatnick; Joe S Mymryk; John Yoo; John W Barrett
Journal:  J Otolaryngol Head Neck Surg       Date:  2013-02-01

Review 10.  Systematic review of the incidence and prevalence of genital warts.

Authors:  Harshila Patel; Monika Wagner; Puneet Singhal; Smita Kothari
Journal:  BMC Infect Dis       Date:  2013-01-25       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.